250 related articles for article (PubMed ID: 32576962)
1. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
[TBL] [Abstract][Full Text] [Related]
2. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
3. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
6. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
7. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
[TBL] [Abstract][Full Text] [Related]
9. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
10. Effects of the omega-3 fatty acid DHA on histone and p53 acetylation in diffuse large B cell lymphoma.
Bakhshi TJ; Way T; Muncy B; Georgel PT
Biochem Cell Biol; 2023 Apr; 101(2):172-191. PubMed ID: 36599133
[TBL] [Abstract][Full Text] [Related]
11. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
[TBL] [Abstract][Full Text] [Related]
12. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
Wei W; Song Z; Chiba M; Wu W; Jeong S; Zhang JP; Kadin ME; Nakagawa M; Yang Y
Leukemia; 2023 Feb; 37(2):396-407. PubMed ID: 36456744
[TBL] [Abstract][Full Text] [Related]
13. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
[TBL] [Abstract][Full Text] [Related]
14. Screening of a large Rubinstein-Taybi cohort identified many novel variants and emphasizes the importance of the CREBBP histone acetyltransferase domain.
Cross E; Duncan-Flavell PJ; Howarth RJ; Hobbs JI; Thomas NS; Bunyan DJ
Am J Med Genet A; 2020 Nov; 182(11):2508-2520. PubMed ID: 32827181
[TBL] [Abstract][Full Text] [Related]
15. Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
Andersen CL; Hasselbalch H; Grønbæk K
Leuk Res; 2012 Apr; 36(4):485-7. PubMed ID: 22177454
[TBL] [Abstract][Full Text] [Related]
16. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
[TBL] [Abstract][Full Text] [Related]
17. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Korzus E
Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.
Andersen CL; Asmar F; Klausen T; Hasselbalch H; Grønbæk K
Leuk Res Rep; 2012; 2(1):1-3. PubMed ID: 24371765
[TBL] [Abstract][Full Text] [Related]
19. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
Haery L; Mussakhan S; Waxman DJ; Gilmore TD
Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia.
Kongkiatkamon S; Pagliuca S; Adema V; Nagata Y; Kerr CM; Walter W; Awada H; Hutter S; Gurnari C; Rogers HJ; Meggendorfer M; Saunthararajah Y; Haferlach T; Visconte V; Maciejewski JP
Leukemia; 2022 Apr; 36(4):1185-1188. PubMed ID: 34845315
[No Abstract] [Full Text] [Related]
[Next] [New Search]
